Fundraising Fox
/People
Sign in

Paul Sekhri

Investor

Investor at eGenesis, Inc. Full-time · Director at Alpine Immune Sciences · Board director at PatientSafe Solutions · Chairman, President, and Chief Executive Officer at Vtvtherapeutics

New York, New York

Writes $100K – $5M checks · typically $1.5M

Find your path to Paul

300 people in our graph can introduce you to Paul.

Each arrow is one introduction. Sign up to fill in the first one.

Ask John Campbell to introduce you to Paul

You →John · together at Resolution Therapeutics (2024–2026) →Paul

Ask Jamie Chen to introduce you to Paul

You →Jamie · together at Vtvtherapeutics →Paul

Ask Sam Okafor to introduce you to Paul

You →Sam · together at Violet Therapeutics →Paul

Sign up to find every way you can get introduced to Paul

  • Your email: the people you already email who know Paul
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Paul
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

About

Paul J. Sekhri is Chairman, President, and Chief Executive Officer of vTv Therapeutics, where he has overseen the company's restructuring and financing to advance a diabetes therapy into Phase III clinical trials. With nearly four decades of experience in pharmaceutical and biotechnology leadership, he has served as Director, Chairman, or Executive Chairman on more than 40 public and private company boards across the United States, Europe, and Israel, with expertise in board governance, capital formation, M&A, and business development. He holds degrees in Membrane Physiology and Zoology from the University of Maryland School of Medicine and is based across North America and Europe.

Director at Alpine Immune Sciences

Intro paths

→

In turn, Paul can intro founders to Alpine Immune Sciences's investors below.

Alpine Immune Sciences's investors · 4

Biotechnology Value FundSan Francisco · since 2021Decheng CapitalMenlo Park · since 2021Frazier Life SciencesPalo Alto · since 2021OrbiMedNew York · $1M – $75M checks · since 2021

Co-founders at Alpine Immune Sciences

MG
Mitchell GoldExecutive Chairman and Chief Executive Officer

Board director at PatientSafe Solutions

Intro paths

→

In turn, Paul can intro founders to PatientSafe Solutions's investors below.

PatientSafe Solutions's investors · 6

Camden PartnersOwings Mills · since 2017HighBar PartnersMenlo Park · since 2017Merck Global Health Innovation FundRahway · $10M checks · since 2017Psilos Groupsince 2017Shoreline Venture ManagementBay Area · $250K – $8M checksTPGSan Francisco · since 2017

Chairman, President, and Chief Executive Officer at Vtvtherapeutics

Intro paths

→

In turn, Paul can intro founders to Vtvtherapeutics's investors below.

Vtvtherapeutics's investors · 2

JDRF T1D FundBostonSamsara BioCapitalMenlo Park · since 2024

Experience

  1. vTv Therapeutics LLCChair, President and CEO, vTv Therapeutics, Inc.current2022 — presentNew York, New York, United States
  2. ApnimedChairperson of the Boardcurrent2026 — presentBoston, MA
  3. Oryn TherapeuticsExecutive Chaircurrent2026 — present
  4. Violet TherapeuticsExecutive Chaircurrent2024 — present
  5. Deep GenomicsMember Board of Directorscurrent2025 — present
  6. Resolution TherapeuticsChair of the Board of Directorscurrent2024 — presentLondon Area, United Kingdom
  7. KayotheraMember Board of Directorscurrent2024 — presentSeattle, Washington, United States
  8. LikeMindsMember Board of Directorscurrent2016 — present
  9. Veeva SystemsBoard Membercurrent2014 — presentSan Francisco Bay Area
  10. AdhereTechBoard Member2024 — 2025New Jersey, United States
  11. Compugen Ltd.Chair of the Board of Directors2017 — 2025Tel Aviv Area, Israel
  12. ORYN THERAPEUTICS, LLCBoard Member2022 — 2024San Diego Metropolitan Area
  13. Longboard PharmaceuticalsChair of the Board of Directors2021 — 2024San Diego, California, United States
  14. Spring DiscoveryBoard Member2021 — 2024San Diego, California, United States
  15. eGenesis, Inc.Board Member2019 — 2024Cambridge, Massachusetts, United States
  16. eGenesis, Inc.President and CEO2019 — 2022New York, New York
  17. IpsenBoard Director2018 — 2023Paris Area, France
  18. Pharming Group N.V.Chair of the Board of Directors2015 — 2023Amsterdam Area, Netherlands
  19. BiomX IncBoard Director2020 — 2022Tel Aviv, Israel
  20. Alpine Immune Sciences, Inc.Board Director2017 — 2020Greater Seattle Area
  21. Petra Pharma CorporationChair of the Board of Directors2016 — 2020New York, New York
  22. Topas Therapeutics GmbHChair of the Board of Supervisory Directors2017 — 2019Hamburg Area, Germany
  23. LyceraPresident and CEO2015 — 2019New York
  24. Enumeral Biomedical Holdings, Inc.Board Director2015 — 2017Greater New York City Area
  25. Nivalis Therapeutics, Inc.Board Director2016 — 2017
  26. HIghline Therapeutics/Versant VenturesOperating Partner2016 — 2017New York
  27. Ascendancy HealthcareBoard Director2012 — 2016San Francisco Bay Area
  28. SanofiSenior Vice President, Integrated Care2014 — 2015Paris Area, France
  29. Teva PharmaceuticalsGroup Executive Vice President, Global Business Development and Chief Strategy Officer2013 — 2014
  30. PatientSafe SolutionsBoard Director2012 — 2014
  31. moksha8Chairman Of The Board2011 — 2013
  32. MacroGenics, Inc.Board Director2010 — 2013
  33. TPG GlobalHead, Biotech Ops Group2009 — 2013
  34. Intercept PharmaceuticalsBoard Director2008 — 2012
  35. KAI PharmaceuticalsBoard Director2007 — 2012
  36. APT PharmaceuticalsBoard Director2007 — 2011
  37. Cerimon Pharmaceuticals, Inc.Founder, President and CEO2004 — 2009
  38. MPM CapitalEIR2004 — 2006
  39. ARIAD Pharmaceuticals, Inc.President and Chief Business Officer2003 — 2004
  40. Northeast Consulting Resources, Inc.Consultant2003 — 2004

Skills & more

Board LeadershipVenture Capital41Pharmaceuticals3Biotechnology99Business Development36Licensing14Pharmaceutical Industry99Technology Transfer67Sop1Biomarkers3Lifesciences37Clinical Trials22
+12 moreCorporate DevelopmentMedical DevicesClinical DevelopmentProduct LaunchNeurologyMarket AccessStrategic PlanningOncologyValidationProduct DevelopmentStrategyCTMS

Languages French

From Paul's professional profile.

Investments

Investor

moksha8 PharmaceuticalsPatientSafe Solutions

Per curated public sources.

Colleagues at eGenesis, Inc. Full-time

Albert Wiegman
Managing Director at Fresenius Medical Care Ventures
Mike Curtis
President & Chief Executive Officer at eGenesis, Inc. Full-time

Frequently asked questions

Who is Paul Sekhri?
Paul J. Sekhri is Chairman, President, and Chief Executive Officer of vTv Therapeutics, where he has overseen the company's restructuring and financing to advance a diabetes therapy into Phase III clinical trials. With nearly four decades of experience in pharmaceutical and biotechnology leadership, he has served as Director, Chairman, or Executive Chairman on more than 40 public and private company boards across the United States, Europe, and Israel, with expertise in board governance, capital formation, M&A, and business development. He holds degrees in Membrane Physiology and Zoology from the University of Maryland School of Medicine and is based across North America and Europe.
Where does Paul Sekhri work?
Paul Sekhri is at eGenesis, Inc. Full-time and Board director at PatientSafe Solutions and Chairman, President, and Chief Executive Officer at Vtvtherapeutics.
What check size does Paul Sekhri write?
Paul Sekhri typically writes checks of $100K – $5M.
What companies has Paul Sekhri invested in?
Investments tracked here include moksha8 Pharmaceuticals, PatientSafe Solutions.
Where did Paul Sekhri go to school?
Paul Sekhri studied at University of Maryland School of Medicine (Neuroscience); University of Maryland (B.Sc., Zoology); Allegheny College (Biology, General).

Founder mafias

Same school

Shared employers